Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment
CPT: Pharmacometrics & Systems Pharmacology · 2026
DOI: 10.1002/psp4.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Bruna Bernar Dias und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics and PK/PD Modeling Laboratory, Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande Do Sul, Porto Alegre, Braz…. Hauptthemen laut MEDLINE: Vildagliptin, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Models, Biological. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brazil (CAPES), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Themen: Simulation in der Pflegeausbildung, Diabetes mellitus
Abstract (Originalsprache)
Vildagliptin (VDG) is a dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor used for type 2 diabetes (T2DM) treatment. Viewing to improve VDG treatment, a population pharmacokinetic (popPK) model was built to describe drug plasma, free liver and muscle concentrations determined by microdialysis in healthy and diabetic animals following 50 mg/kg i.v. bolus administration. A four‐compartment popPK model with linear elimination and bidirectional transport between tissues and the central compartment described the data with diabetes as a covariate in Q 1 and Q out,liver . The pharmacokinetic parameters of VDG were scaled to humans using allometry, and used to simulate VDG tissue concentrations in patients with T2DM and relate them with the DPP‐4 inhibition by an I max model. The efficacy of VDG was evaluated considering 80% and 92% DP‐IV inhibition during the entire dosing interval. VDG 100 mg q24 h achieved 80% DPP‐4 inhibition in plasma, but not in tissues. Although q12 h dosing interval reached 80% enzyme inhibition in plasma for > 25 mg doses, only the 100 mg reached this goal in muscle. The 92% enzyme inhibition was achieved in plasma for 50 and 100 mg q12 h but none of the dose regimens investigated reached this inhibition in tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacokinetics and PK/PD Modeling Laboratory, Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil.
ORCID-Profile: Bruna Bernar Dias, Laura Ben Olivo, Bibiana Verlindo de Araújo
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brazil (CAPES)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Dias, B. B., Olivo, L. B., & de Araújo, B. V. (2026). Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70165
Vancouver
Dias BB, Olivo LB, de Araújo BV. Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70165
BibTeX
@article{Dias2026,
author = {Dias, Bruna Bernar and Olivo, Laura Ben and de Araújo, Bibiana Verlindo},
title = {Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
doi = {10.1002/psp4.70165}
}
EUVIMED